DR. PAUL J. SHAMI, MD
Osteopathic Medicine at Circle Of Hope Dr, Salt Lake City, UT

License number

Utah 345232-1205

Personal information

See more information about PAUL J. SHAMI at radaris.com

Name

Address

Phone

Paul Shami

9758 Cervantes Cir, Sandy, UT 84092

Paul Shami

9758 S Cervantes Cir, Sandy, UT 84092

Paul Shami

3254 Walnut Cir, Salt Lake City, UT 84121

Professional information

See more information about PAUL J. SHAMI at trustoria.com

Associate Professor Of Oncology At University Of Utah

Position:

Professor at Hematology and Hematologic Malignancies, Adjunct Professor at University of Utah, Professor at University ofUtah Medical Center, Chief Medical Officer at JSK Therapeutics Inc, Professor of Hematology at University of Utah, Professor at University of Utah, Professor of Medicine at University of Utah Medical Center

Location:

Greater Salt Lake City Area

Industry:

Hospital & Health Care

Work:

Hematology and Hematologic Malignancies since Jan 2010 - Professor University of Utah since 2010 - Adjunct Professor University ofUtah Medical Center since Jan 2009 - Professor JSK Therapeutics Inc since Jan 2008 - Chief Medical Officer University of Utah since 1997 - Professor of Hematology University of Utah since Sep 1997 - Professor University of Utah Medical Center since Sep 1997 - Professor of Medicine Hematology/Oncology Section, SLC VA Medical Center Jan 2002 - Jan 2005 - Member and Clinical Investigator University of Utah Medical Center Jan 1998 - Jan 2002 - Assistant Professor University of Utah Medical Center Jan 1997 - Jan 1998 - Assistant Professor Hematology/Oncology Section, Durham V.A. Medical Center Jan 1996 - Jan 1997 - Clinical Director Duke University Medical Center Jan 1996 - Jan 1997 - Assistant Professor Durham V.A. Medical Center Jan 1995 - Jan 1997 - Special Hematology Laboratory Director Hematology/Oncology Section, Durham V.A. Medical Center Jan 1994 - Jan 1997 - Staff Physician Duke University Medical Center Jan 1994 - Jan 1996 - Associate

Education:

American University of Beirut Faculty of Arts and Sciences
BS, Chemistry

Dr. Paul J Shami - MD (Doctor of Medicine)

Hospitals:

Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132

Education:

Medical Schools
American University of Beirut / Faculty of Medicine

Paul J Shami, Salt Lake City UT

Specialties:

Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology

Work:

Hematology/Oncology
1950 Circle Of Hope Dr, Salt Lake City, UT 84112 University of Utah Hospitals & Clinics
50 N Medical Dr, Salt Lake City, UT 84132

Education:

American University Of Beirut (1988)

Novel Gene Rno Upregulated In Leukemia Cells By Nitric Oxide And Dmso

US Patent:

2001002, Oct 11, 2001

Filed:

Mar 6, 2001

Appl. No.:

09/799983

Inventors:

Paul Shami - Salt Lake City UT, US
Charles Parker - Salt Lake City UT, US

International Classification:

C12Q001/68, G01N033/574, C12P021/02, C12N005/06

US Classification:

435/069100, 435/325000, 435/007230, 435/006000

Abstract:

The present invention relates to a novel human gene which has been shown to induce differentiation of cancer cells. The gene is regulated by NO and is named rno. Three isoforms of rno have been isolated and purified, rno-1 (SEQ ID NO: 1), rno-2 (SEQ ID NO: 3), and rno-3 (SEQ ID NO: 5). The rno isoforms each code for a separate amino acid sequence (SEQ ID NOS: 2, 4, & 5 ). The present invention also provides recombinant vectors comprising nucleic acid molecules that code for the rno gene products. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for the rno gene products are operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for the rno gene products (SEQ ID NOS: 2, 4, & 5). The gene products have been shown to induce AML cell differentiation and apoptosis.

Vivo Use Of Glutathione S-Transferase Activated Nitric Oxide Donors

US Patent:

2005017, Aug 4, 2005

Filed:

Mar 21, 2003

Appl. No.:

10/508744

Inventors:

Paul Shami - Salt Lake City UT, US

International Classification:

A61K031/655, A61K031/506, A61K031/495

US Classification:

514150000, 514255010, 514252140

Abstract:

The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype.